Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Ara h 3

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    17 result(s) found for: Ara h 3. Displaying page 1 of 1.
    EudraCT Number: 2011-000749-19 Sponsor Protocol Number: SPON934-11 Start Date*: 2011-06-29
    Sponsor Name:Cardiff University
    Full Title: Bloodwise and NCRI Working Group Pick a Winner Programme (LI-1) Trial
    Medical condition: Acute myeloid leukemia and high-risk myelodysplastic syndrome
    Disease: Version SOC Term Classification Code Term Level
    19.0 10005329 - Blood and lymphatic system disorders 10005329 Blood and lymphatic system disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DK (Completed)
    Trial results: View results
    EudraCT Number: 2018-003323-10 Sponsor Protocol Number: V712-305(EPOPEX) Start Date*: Information not available in EudraCT
    Sponsor Name:DBV TECHNOLOGIES S.A.
    Full Title: EPITOPE OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM CLINICAL BENEFIT AND SAFETY OF DBV712 IN PEANUT-ALLERGIC CHILDREN (EPOPEX)
    Medical condition: Peanut allergy
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004870 10034202 Peanut allergy LLT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: IE (Completed) GB (GB - no longer in EU/EEA) NL (Trial now transitioned) DE (Trial now transitioned) FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-005038-53 Sponsor Protocol Number: FIM-PRU-2018-01 Start Date*: 2019-05-16
    Sponsor Name:Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina Y Salud (FIMABIS)
    Full Title: Randomized double-blind, placebo-controlled study evaluate the efficacy and mechanisms involved in immunotherapy Sublingual specifies with Pru p 3 (Pru p 3-ITSL) in patients with allergy to nsLTP w...
    Medical condition: LTP syndrome.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021428 - Immune system disorders 10016946 Food allergy PT
    Population Age: Children, Under 18, Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-000854-32 Sponsor Protocol Number: RA 2.0 Start Date*: 2006-05-29
    Sponsor Name:Vienna Medical University
    Full Title: Rituximab in Rheumatoid Arthritis in Patients Who Failed Therapy With TNF-Blockers
    Medical condition: Rheumatoid Arthritis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2006-004673-98 Sponsor Protocol Number: ML 20538 Start Date*: 2006-10-16
    Sponsor Name:Roche (Hungary) Ltd.
    Full Title: Efficacy of Rituximab treatment in patients with rheumatoid arthritis having inadequate response to TNF blocker
    Medical condition: To investigate the efficacy of treatment with Rituximab (MabThera®) in patients with active RA whose current treatment with one or more TNF-blocker (Etanercept - Enbrel®, Infliximab – Remicade® or ...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: View results
    EudraCT Number: 2011-001929-24 Sponsor Protocol Number: 1392-H-199 Start Date*: 2011-09-19
    Sponsor Name:Fundación para la Investigación Biomédica del Hospital 12 de Octubre
    Full Title: Randomised, open-label, crossover clinical trial to evaluate the antiproteinuric effect of three different types of diuretics (hydrochlorothiazide, amiloride and spironolactone) in patients with ch...
    Medical condition: Chronic proteinuric nephropathies
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-003075-37 Sponsor Protocol Number: NLG-LBC-04 Start Date*: 2004-12-20
    Sponsor Name:Nordic Lymphoma Group
    Full Title: CHOEP-14 + rituximab with CNS prophylaxis in patients less than 65 years with Diffuse Large B-Cell Lymphoma/Follicular Lymphoma grade III, stage II-IV with risk factors (age adjusted IPI) ≥ 2. A ph...
    Medical condition: 18-64 year old patients having primary diffuse large B-cell lymphoma (DLBCL) with risk factors (age adjusted IPI≥2), or follicular lymphoma grade III
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-001553-10 Sponsor Protocol Number: CACZ885A2204 Start Date*: 2007-06-19
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A 26-week, phase II, multi-center, randomized, double-blind, placebo-controlled study to assess the response to treatment (ACR50) and to determine a biomarker profile in responders to ACZ885 (anti-...
    Medical condition: Early Rheumatoid Arthritis in adults
    Disease: Version SOC Term Classification Code Term Level
    8.1 10039073 Rheumatoid arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) NL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-000760-24 Sponsor Protocol Number: ACT5488 Start Date*: 2007-06-21
    Sponsor Name:sanofi-aventis recherche & développement
    Full Title: Activity and safety of oral administration of SSR150106XB for the reduction of inflammation in patients with active rheumatoid arthritis (RA): A 4-week, multi-center, randomized, double-blind, plac...
    Medical condition: Patients with active rheumatoid arthritis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2020-000142-34 Sponsor Protocol Number: ITCC-092/IST11028 Start Date*: 2020-09-15
    Sponsor Name:Princess Máxima Center for pediatric oncology
    Full Title: A Phase Ib study of Vyxeos® (liposomal daunorubicin and cytarabine) in combination with Clofarabine in children with relapsed/refractory AML, ITCC-092
    Medical condition: Relapsed or refractory pediatric acute myeloid leukemia
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10060558 Acute myeloid leukemia recurrent LLT
    21.1 100000004864 10081514 Acute myeloid leukemia refractory LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: NL (Trial now transitioned) AT (Trial now transitioned) DK (Trial now transitioned) IT (Trial now transitioned) DE (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-003514-34 Sponsor Protocol Number: HCTvs.CTelderlyAML Start Date*: 2009-03-26
    Sponsor Name:European Society for Blood and Marrow Transplantation EBMT
    Full Title: A Randomized Phase III study comparing conventional chemotherapy to low dose total body irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors as co...
    Medical condition: Acute Myeloid Leukaemia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000881 Acute myeloid leukaemia (in remission) PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) NL (Prematurely Ended) FR (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2007-005506-42 Sponsor Protocol Number: NHL-HIV+ Start Date*: 2007-10-19
    Sponsor Name:OSPEDALE S. RAFFAELE
    Full Title: HIGH-DOSE SEQUENTIAL CHEMOTHERAPY AND RITUXIMAB (R-HDS) IN HIV+ PATIENTS WITH NON-HODGKIN LYMPHOMA (NHL) REFRACTORY OR RELAPSED AFTER 1st LINE TREATMENT
    Medical condition: HIV+ PATIENTS WITH NON-HODGKIN LYMPHOMA (NHL) REFRACTORY OR RELAPSED AFTER 1st LINE TREATMENT
    Disease: Version SOC Term Classification Code Term Level
    10029547 PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-000620-17 Sponsor Protocol Number: DRKS00005503 Start Date*: 2014-04-28
    Sponsor Name:Landeshauptstadt Stuttgart, represented by the Executive Medical Director Klinikum Stuttgart
    Full Title: High-dose chemotherapy and autologous stem cell transplant or consolidating conventional chemotherapy in primary CNS lymphoma - randomized phase III trial
    Medical condition: Primary CNS lymphoma (PCNSL) accounts for 1 to 2% of all Non-Hodgkin's lymphomas (NHL) and for 2 to 7% of all primary CNS tumors. It's incidence has increased over the past 30 years, particularly i...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) DK (Completed) NO (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-000929-32 Sponsor Protocol Number: JCAR017-BCM-003 Start Date*: 2018-08-21
    Sponsor Name:Celgene Corporation
    Full Title: A global randomized multicenter Phase 3 trial to compare the efficacy and safety of JCAR017 to standard of care in adult subjects with high-risk, transplant-eligible relapsed or refractory aggressi...
    Medical condition: Transplant-eligible relapsed or refractory (R/R) aggressive B-cell Non Hodgkin Lymphoma (B-NHL)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10029593 Non-Hodgkin's lymphoma NOS LLT
    20.0 10005329 - Blood and lymphatic system disorders 10025320 Lymphomas non-Hodgkin's B-cell HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) BE (Completed) ES (Ongoing) GB (GB - no longer in EU/EEA) SE (Completed) NL (Ongoing) IT (Completed)
    Trial results: View results
    EudraCT Number: 2004-004917-41 Sponsor Protocol Number: WX17801 Start Date*: 2005-09-05
    Sponsor Name:Aspreva International Ltd.
    Full Title: A prospective, randomized, active controlled, parallel group, multi-center trial to assess the efficacy and safety of mycophenolate mofetil (MMF) in inducing response and maintaining remission in s...
    Medical condition: Lupus Nephritis
    Disease: Version SOC Term Classification Code Term Level
    4.1 10025140 Low
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) HU (Completed) CZ (Completed) ES (Completed) BE (Completed) PT (Completed) AT (Prematurely Ended) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-002549-39 Sponsor Protocol Number: Ponatinib-1501 Start Date*: 2020-12-07
    Sponsor Name:Takeda Development Center Americas, Inc.
    Full Title: A Pivotal Phase 1/2, Single-Arm, Open-label Study to Evaluate the Safety and Efficacy of Ponatinib With Chemotherapy in Pediatric Patients With Philadelphia Chromosome-Positive (Ph+) Acute Lympho...
    Medical condition: acute lymphoblastic leukemia
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10000845 Acute lymphoblastic leukemia LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Completed) CZ (Completed) NL (Prematurely Ended) IT (Prematurely Ended) PL (Prematurely Ended) PT (Prematurely Ended) ES (Completed)
    Trial results: View results
    EudraCT Number: 2007-004270-43 Sponsor Protocol Number: AIEOP-BFMALL2009 Start Date*: Information not available in EudraCT
    Sponsor Name:Universitätsklinikum Schleswig-Holstein, Campus Kiel
    Full Title: International collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia
    Medical condition: acute lymphoblastic leukemia in children and adolescents 1 to <18 years of age
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10000845 Acute lymphoblastic leukemia LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) AT (Completed) IT (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Jun 08 14:43:00 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA